Concept And Indian Scenario

  • Newborn screening (NBS) is a secondary prevention strategy that identifies treatable endocrine, metabolic, and genetic disorders presymptomatically before irreversible brain damage or death occurs.
  • India has approximately 25 to 26 million births annually, representing the largest newborn cohort globally.
  • Consanguinity in select regions, high birth prevalence of inborn errors of metabolism, and delayed diagnosis make screening a high clinical priority.
  • A comprehensive newborn screen incorporates three pillars: dried blood spot metabolic screening, critical congenital heart disease pulse oximetry, and universal hearing screening.

Dried Blood Spot (DBS) Screening

  • Timing: Blood is collected between 48 and 72 hours of life (minimum $\ge 24\text{ hours}$ after initiating milk feeds).
  • Sampling before 24 hours causes false-positive TSH elevations due to the physiological neonatal TSH surge and false-negative amino acid/acylcarnitine results due to insufficient protein substrate intake.
  • Method: Puncture the medial or lateral plantar border of the heel using an automated spring-loaded lancet. Avoid the posterior calcaneus to prevent osteomyelitis.
  • Blood is applied to Whatman 903 or Ahlstrom 226 filter paper cards and air-dried horizontally for 3 to 4 hours at room temperature.

Core Essential Panel For India

The Indian Academy of Pediatrics (IAP) and ICMR recommend a priority minimum panel for universal implementation:

DisorderPrimary MarkerScreening CutoffClinical Consequence If Missed
Congenital Hypothyroidism (CH)Thyroid Stimulating Hormone (TSH)Blood spot TSH >15 to 20 $\mu\text{IU/mL}$Severe irreversible intellectual disability (cretinism); incidence in India is high ($\approx 1:1,000\text{ to }1:1,500$).
Congenital Adrenal Hyperplasia (CAH)17-$\alpha$-hydroxyprogesterone (17-OHP)Stratified by gestational age and birth weightFatal salt-wasting shock at day 7 to 14 of life; incorrect gender assignment in virilized females.
G6PD DeficiencyG6PD enzyme activity (fluorometric assay)<2.0 to 2.5 U/g HbSevere neonatal hyperbilirubinemia, kernicterus, acute drug- or infection-induced hemolysis.

Expanded Screening By Tandem Mass Spectrometry (MS/MS)

  • Tandem Mass Spectrometry (MS/MS) analyzes both amino acids and acylcarnitines simultaneously from a single 3-mm dried blood spot punch in under 2 minutes.
  • It can identify over 40 to 50 inborn errors of metabolism:
    • Amino Acidopathies: Phenylketonuria (elevated phenylalanine), Maple Syrup Urine Disease (elevated leucine, isoleucine, valine), Homocystinuria (elevated methionine).
    • Organic Acidemias: Methylmalonic acidemia (elevated C3 carnitine), Propionic acidemia, Isovaleric acidemia (elevated C5 carnitine), Glutaric aciduria type 1.
    • Fatty Acid Oxidation Defects: Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency (elevated C8 carnitine), VLCAD, LCHAD (prevents fasting hypoketotic hypoglycemia and sudden unexpected infant death).

Point-Of-Care Delivery Point Screening

Critical Congenital Heart Disease (CCHD) Screening

  • Performed at $\ge 24\text{ hours of life}$ using motion-tolerant pulse oximeters.
  • Probes are attached to the right hand (pre-ductal) and either foot (post-ductal).
  • Pass: $SpO_2 \ge 95\%$ in both limbs and difference $\le 3\%$.
  • Fail: $SpO_2 < 90\%$ in either limb $\rightarrow$ Urgent echocardiography.
  • Equivocal: $SpO_2\ 90\text{–}94\%$ or $>3\%$ difference $\rightarrow$ Repeat in 1 hour; if fail on 3 measurements, perform echocardiography.

Universal Hearing Screening (JCIH 1-3-6 Guidelines)

  • Screening completed by 1 month of age, confirmatory diagnostic testing by 3 months, and early intervention (hearing aids/cochlear implants) initiated by 6 months.
  • Two-Stage Modality:
    • Step 1: Automated Otoacoustic Emissions (AOAE) assesses cochlear outer hair cell function.
    • Step 2: Automated Auditory Brainstem Response (AABR) is mandatory for all NICU admissions (>5 days), hyperbilirubinemia requiring exchange transfusion, asphyxia, or AOAE failure. AABR detects Auditory Neuropathy Spectrum Disorder (ANSD) which AOAE misses.

National Programs And State Models (RBSK)

  • Rashtriya Bal Swasthya Karyakram (RBSK):
    • Flagship national child health screening program under the National Health Mission (NHM) covering children from 0 to 18 years for the 4Ds:
      1. Defects at birth (Neural tube defects, cleft lip/palate, club foot, congenital cataract, congenital heart disease).
      2. Deficiencies (Anemia, Vitamin A and D deficiencies, severe acute malnutrition).
      3. Diseases (Skin conditions, otitis media, rheumatic heart disease).
      4. Developmental delays and disabilities (Vision, hearing, motor impairment, autism).
    • Cases identified are linked to District Early Intervention Centres (DEIC) for free medical, surgical, and therapeutic management.
  • State Implementation Pioneers:
    • Goa: First Indian state to implement universal newborn metabolic screening using TMS across all public and private births since 2008.
    • Kerala ("NeMo" Project): State-wide screening covering congenital hypothyroidism, CAH, G6PD, and metabolic disorders integrated into electronic tracking.
    • Chandigarh & Delhi: Systematic hospital-based universal screening models with established diagnostic recall networks.

Molecular And Genomic Frontiers

  • PCR testing on dried blood spots identifies T-cell receptor excision circles (TREC) to detect Severe Combined Immunodeficiency (SCID).
  • PCR screening for homozygous SMN1 exon 7 deletion enables presymptomatic diagnosis and gene therapy for Spinal Muscular Atrophy.
  • Genomic newborn screening using targeted next-generation sequencing is being piloted for dozens of monogenic conditions.